Developing a comprehensive framework for Real-World Evidence in regulatory decisions: global lessons with applications for the Global South.

Purpose: The integration of Real-World Evidence (RWE) into regulatory frameworks has gained global interest to complement traditional clinical data, particularly where randomized controlled trials may be limited. RWE refers to clinical evidence derived from the analysis of Real-World Data (RWD), including information routinely collected from sources such as electronic health records, claims databases and registries. The increasing reliance on large-scale digital data also raises challenges related to privacy, inclusivity and equity, highlighting the need for transparent and socially responsible approaches. This study developed a consensus-based framework for incorporating RWE into regulatory decision-making in Colombia, with potential applications in similar Global South contexts. Methods: A two-phase design was applied. Phase I was a scoping review following Joanna Briggs Institute guidelines to identify RWE frameworks and guidelines. Searches in databases and regulatory agencies yielded 61 relevant documents. In Phase II, an expert panel of ten professionals in RWE, RWD, and regulation refined preliminary recommendations through a modified Delphi approach, reaching consensus on their applicability. Findings: The scoping review revealed a high concentration of RWE studies originating from the United States and Europe, highlighting contributions by agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in guiding RWE for regulatory decisions, particularly in oncology and rare diseases. The expert panel validated 25 recommendations, grouped into six clusters addressing selection, transparency, stakeholder engagement, analytical validation, accessibility and capacity. Implications: This framework guides Colombia and the Global South in strengthening evidence-based regulation. It emphasizes governance, transparency, inclusivity and privacy safeguards, supporting equitable decision-making aligned with international standards.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-04-17
DOI
https://doi.org/10.1332/17442648y2026d000000088
Primary Topic
Health Systems, Economic Evaluations, Quality of Life
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Developing a comprehensive framework for Real-World Evidence in regulatory decisions: global lessons with applications for the Global South.

Andrés Cardona-Mendoza, Carlos Felipe Escobar, Laura Angélica Pineda, David Díaz-Báez et al.
PubMed
Health Systems, Economic Evaluations, Quality of Life
article

Developing a comprehensive framework for Real-World Evidence in regulatory decisions: global lessons with applications for the Global South.

Andrés Cardona-Mendoza, Carlos Felipe Escobar, Laura Angélica Pineda, David Díaz-Báez, Juan Camilo Tocora, Fabio Sierra-Matamoros, Hernan Felipe Guillen-Burgos
article en

Abstract

Purpose: The integration of Real-World Evidence (RWE) into regulatory frameworks has gained global interest to complement traditional clinical data, particularly where randomized controlled trials may be limited. RWE refers to clinical evidence derived from the analysis of Real-World Data (RWD), including information routinely collected from sources such as electronic health records, claims databases and registries. The increasing reliance on large-scale digital data also raises challenges related to privacy, inclusivity and equity, highlighting the need for transparent and socially responsible approaches. This study developed a consensus-based framework for incorporating RWE into regulatory decision-making in Colombia, with potential applications in similar Global South contexts. Methods: A two-phase design was applied. Phase I was a scoping review following Joanna Briggs Institute guidelines to identify RWE frameworks and guidelines. Searches in databases and regulatory agencies yielded 61 relevant documents. In Phase II, an expert panel of ten professionals in RWE, RWD, and regulation refined preliminary recommendations through a modified Delphi approach, reaching consensus on their applicability. Findings: The scoping review revealed a high concentration of RWE studies originating from the United States and Europe, highlighting contributions by agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in guiding RWE for regulatory decisions, particularly in oncology and rare diseases. The expert panel validated 25 recommendations, grouped into six clusters addressing selection, transparency, stakeholder engagement, analytical validation, accessibility and capacity. Implications: This framework guides Colombia and the Global South in strengthening evidence-based regulation. It emphasizes governance, transparency, inclusivity and privacy safeguards, supporting equitable decision-making aligned with international standards.

PubMed
Universidad El Bosque (CO), Pontificia Universidad Javeriana (CO), Fundación para la Educación y el Desarrollo Social (CO), J.M. Huber Corporation (United States) (US), Misericordia University (US)
Peace, Justice and strong institutions
Openalex Percentile: Top 3%
Health Systems, Economic Evaluations, Quality of Life
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.